Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies.


Journal

Ageing research reviews
ISSN: 1872-9649
Titre abrégé: Ageing Res Rev
Pays: England
ID NLM: 101128963

Informations de publication

Date de publication:
06 2023
Historique:
received: 26 12 2022
revised: 06 03 2023
accepted: 13 03 2023
medline: 9 5 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Alzheimer's disease (AD) is the most common type of dementia and seriously affects human life and health. Kaempferol (KMP) is a common flavonoid, that is mainly derived from the rhizomes of Kaempferol galanga L. and is widely found in various fruits and vegetables. Previous studies have suggested that KMP has multiple pharmacological activities. However, the anti-AD mechanism of KMP has not been elucidated. This systematic review aims to summarize the existing preclinical experiments on KMP, further confirm the therapeutic effect of KMP in an AD model, and summarize the possible mechanism by which KMP exerts anti-AD effects. Electronic databases, including PubMed, China National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang, were searched using the keywords of 'Kaempferol,' 'KMP,' 'pharmacology,' and 'Alzheimer's disease'. We evaluated the reliability of the 12 included studies, and the results showed that the anti-AD mechanism of KMP was reliable and that the prospect of KMP in the treatment of cognitive impairment was promising. We comprehensively assessed the neuroprotective effects of KMP in in vivo and in vitro models of AD. These studies shown that KMP ameliorated AD through several mechanisms, including its antioxidant, anti-inflammatory, anti-apoptotic, and anti-acetylcholinesterase effects. KMP may exert anti-AD effects through various mechanisms and is a potential drug with broad prospects for the treatment of AD.

Sections du résumé

BACKGROUND
Alzheimer's disease (AD) is the most common type of dementia and seriously affects human life and health. Kaempferol (KMP) is a common flavonoid, that is mainly derived from the rhizomes of Kaempferol galanga L. and is widely found in various fruits and vegetables. Previous studies have suggested that KMP has multiple pharmacological activities. However, the anti-AD mechanism of KMP has not been elucidated.
METHODS
This systematic review aims to summarize the existing preclinical experiments on KMP, further confirm the therapeutic effect of KMP in an AD model, and summarize the possible mechanism by which KMP exerts anti-AD effects. Electronic databases, including PubMed, China National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang, were searched using the keywords of 'Kaempferol,' 'KMP,' 'pharmacology,' and 'Alzheimer's disease'.
RESULTS
We evaluated the reliability of the 12 included studies, and the results showed that the anti-AD mechanism of KMP was reliable and that the prospect of KMP in the treatment of cognitive impairment was promising. We comprehensively assessed the neuroprotective effects of KMP in in vivo and in vitro models of AD. These studies shown that KMP ameliorated AD through several mechanisms, including its antioxidant, anti-inflammatory, anti-apoptotic, and anti-acetylcholinesterase effects.
CONCLUSION
KMP may exert anti-AD effects through various mechanisms and is a potential drug with broad prospects for the treatment of AD.

Identifiants

pubmed: 36924572
pii: S1568-1637(23)00069-7
doi: 10.1016/j.arr.2023.101910
pii:
doi:

Substances chimiques

Kaempferols 0
Antioxidants 0

Types de publication

Systematic Review Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101910

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Xiaoyu Dong (X)

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China. Electronic address: dongxy@sj-hospital.org.

Siyu Zhou (S)

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China.

Jianfei Nao (J)

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China. Electronic address: 18940256567@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH